A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus

Activo, no reclutaFase 3ClinicalTrials.gov

ID: NCT04963296Tipo: INTERVENTIONALInicio: 26 de oct de 2021Fin estimado: 14 de mar de 2028

Traducción no disponible, mostrando original

Resumen

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 75 YearsSexo: ALL

Criterios de inclusión

Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria \>=12 weeks prior to screening
Anti-nuclear antibody (ANA) \>=1:80, or anti-dsDNA and/or anti-Sm antibodies above the upper limit of normal (ULN), as determined by the central laboratory at screening
Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
High disease activity at screening, based on; BILAG-2004 (Category A disease in \>=1 organ system and/or Category B disease in \>=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score \>=8) and Physician's Global Assessment (PGA) (score \>=1.0 on a 0 to 3 visual analogue scale \[VAS\])
High disease activity on Day 1, based on; SLEDAI-2K (score \>=8) and PGA (score \>=1.0 on a 0 to 3 VAS)
Current receipt of \>=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials, conventional immunosuppressants
The Medical Monitor may be consulted if there are any questions related to eligibility criteria

Criterios de exclusión

Pregnancy or breastfeeding
Presence of significant lupus-associated renal disease and/or renal impairment
Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
Known active infection of any kind or recent major episode of infection
Intolerance or contraindication to study therapies

Intervenciones

drug

Obinutuzumab

Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.

drug

Placebo

Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.

drug

Acetaminophen/Paracetamol

Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

drug

Diphenhydramine hydrochloride

Diphenhydramine 50 mg will be administered as premedication prior to infusions.

drug

Methylprednisolone

Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.

Ubicaciones

Organizacion Medica de Investigacion

Buenos Aires, Argentina

DOM Centro de Reumatología

Buenos Aires, Argentina

Centro de Investigaciones Médicas Tucuman

San Miguel, Argentina

Patrocinadores

PrincipalHoffmann-La Roche

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase III, Randomized, Double-Blind, Placebo-Controlled... | EligiMed